Clinical Impact of Digitalis Therapy in a Large Multicenter Cohort of CRT-Recipients
Julia W Erath1, Nikolett Vigh2, Balazs Muk2,3
1Department of Cardiology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.
Insights
Digitalis therapy in patients with cardiac resynchronization therapy (CRT) did not affect mortality. However, it was linked to a poorer CRT response and increased ventricular arrhythmias, though it reduced cardiac rehospitalization.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- The use of digitalis in severe heart failure patients receiving cardiac resynchronization therapy (CRT) remains controversial.
- Observational studies are crucial for understanding digitalis effects in this complex patient population.
Purpose of the Study:
- To assess the impact of digitalis therapy on all-cause mortality in patients undergoing CRT.
- To evaluate secondary endpoints including CRT response, echocardiographic improvements, ICD shocks, and rehospitalization rates.
Main Methods:
- A large, observational study involving 552 consecutive CRT-defibrillator recipients across three European centers.
- Digitalis use was recorded at CRT implantation; follow-up averaged 37 months.
- Multivariate Cox-regression and propensity score matching were employed to analyze mortality and secondary outcomes.
Main Results:
- Digitalis users (40%) had more comorbidities like atrial fibrillation, lower ejection fraction (LVEF), and higher NYHA class.
- No significant difference in all-cause mortality was observed between digitalis users and non-users, even after adjustment (adjusted HR=1.04) and propensity matching (HR=1.11).
- Digitalis was associated with reduced CRT response (NYHA class and LVEF improvement) and increased ventricular arrhythmias requiring ICD shocks, but significantly lower cardiac rehospitalization (HR=0.58).
Conclusions:
- Digitalis therapy demonstrated no impact on mortality in CRT recipients.
- The therapy was linked to diminished CRT response and increased susceptibility to ventricular arrhythmias requiring ICD shocks.
- Digitalis use was associated with a positive effect on reducing cardiac rehospitalization during follow-up.
Abstract:
(1) Introduction: Digitalis use in patients with severe heart failure is controversial. We assessed the effects of digitalis therapy on mortality in a large, observational study in recipients of cardiac resynchronization therapy (CRT). (2) Methods: Consecutive patients receiving a CRT-defibrillator in three European tertiary referral centers were enrolled and followed-up for a mean 37 months ± 28 months. Digitalis use was assessed at the time of CRT implantation. A multivariate Cox-regression model and propensity score matching were used to determine all-cause mortality as the primary endpoint. CRT-response (defined as improvement of ≥1 NYHA class), echocardiographic improvement (defined as improvement of LVEF of ≥ 5%) and incidence of ICD shocks and rehospitalization were assessed as secondary endpoints in a subgroup of patients. (3) Results: The study comprised 552 CRT-recipients with standard indications, including 219 patients (40%) treated with digitalis. Compared to patients without digitalis, they had more often atrial fibrillation, poorer LVEF and a higher NYHA class (all p ≤ 0.002). Crude analysis of all-cause mortality demonstrated a similar relative risk of death for patients with and without digitalis (HR = 1.14; 95% CI 0.88-1.5; p = 0.40). After adjustment for independent predictors of mortality, digitalis therapy did not alter the risk for death (adjusted HR = 1.04; 95% CI 0.75-1.45; p = 0.82). Furthermore, in comparison to 286 propensity-score-matched patients, mortality was not affected by digitalis intake (propensity-adjusted HR = 1.11; 95% CI 0.72-1.70; p = 0.64). A CRT-response was predominant in digitalis non-users, concerning both improvement of HF symptoms and LVEF (NYHA p < 0.01; LVEF p < 0.01), while patients on digitalis had more often ventricular tachyarrhythmias requiring ICD shock (p = 0.01); although, rehospitalization for cardiac reasons was significantly lower among digitalis users compared to digitalis non-users (HR = 0.58; 95% C. I. 0.40-0.85; p = 0.01). (4) Conclusions: Digitalis therapy had no effect on mortality, but was associated with a reduced response to CRT and increased susceptibility to ventricular arrhythmias requiring ICD shock treatment. Although, digitalis administration positively altered the likelihood for cardiac rehospitalization during follow-up.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...


